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The effect of alkylating agents on histone acetyltransferase (EC 2.3.1.48) activity and thymidine incorporation was investigated in benign and malig- 
nant proliferating rat liver tissue and compared with the effect in normal non-proliferating rat liver tissue. In both, benign and malignant proliferating 
tissue, but not in quiescent issue, the histone acetylation is depressed by alkylating agents and this depression correlates with the inhibition of 
the thymidine incorporation. This effect suggests that the depression of the replication associated histone acetylation may be an important factor 
for the antiproliferative activity of alkylating agents. 
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1. INTRODUCTION 
The posttranslational acetylation of histones is in- 
volved in a number of cell processes like cell differen- 
tiation [ 11, transcription [2] and replication [3,4]. 
Horiuchi et al. [5] first described differences between 
histone acetylation of normal and corresponding malig- 
nant cells and showed that histone acetylation and 
deacetylation occurs faster in nuclei from AH 66 
hepatoma cells than in fetal, regenerating or adult nor- 
mal liver. A replication associated histone acetylation 
was observed recently in rats after partial hepatectomy 
[6] as well as in various tumors [7]. 
days after inoculation. The alkylating antitumor agents were injected 
i.p. 4 h before harvesting the cells. Rats of the same sex, strain and 
weight as described above were partially hepatectomized [lo]. The 
livers were isolated immediately and put into 0.14 M NaCl. The fur- 
ther procedure was as described previously [6]. The concentration of 
N-mustard was 5 x 10v5 mol/kg and of Mafosfamid (ASTA 27557) 
3 x 10m4 mol/kg. N-mustard (methyl-b&(2-chloroethyl)amine) was 
purchased from Sigma Chemicals, Munich, FRG. 4-Sulfonatoethyl- 
thiocyclophosphamide (Mafosfamid, ASTA 27557) was a gift from 
ASTA-Werke AG, Bielefeld, FRG. 
2.2. Preparation of nuclei 
It seemed interesting to investigate whether 
replication-linked histone acetylation is sensitive to 
alkylating agents. The capacity of alkylating agents like 
N-mustard or cyclophosphamide to depress the acetyla- 
tion of core histones in tumor cells was shown in 
previous reports [8,9]. Keeping the above considera- 
tions in mind, we thought it reasonable to compare the 
depression of histone acetylation and proliferation in 
malignant tissue (hepatoma AS30D) with benign pro- 
liferating tissue (regenerating rat liver) and with normal 
non-proliferating untreated rat liver. 
All the procedures were carried out at 0 to 4°C. Livers were 
homogenized in 3 vols STKM (0.25 M sucrose, 25 mM KCI, 5 mM 
MgClz, 50 mM Tris-HCl, pH 7.9) using a Potter homogenizer. Liver 
or hepatoma cells were suspended in STKM and sedimented by cen- 
trifugation at 1000 x g. Cells were resuspended in STKM containing 
0.1% NP40, dounced 20-30 times and nuclei were pelleted at 1000 
x g. Nuclei were washed two times using STC (0.34 M sucrose, 
2 mM CaClr, 100 mM Tris, pH 7.9). All buffers contained 10 mM 
Na-butyrate, 0.1 mM phenylmethylsulfonylfluoride, 0.1% fl- 
mercaptoethanol. 
2.3. Acetylation of histones in isolated nuclei 
2. MATERIALS AND METHODS 
2.1. Preparation of cells 
Hepatoma AS30D was grown i.p. by inoculation in male 
Sprague-Dawley rats (250-300 g) and propagated by transplantation 
of the tumor every 12 days. Tumor cells were harvested at various 
Nuclei (1.5 x 10’ approximately 1.2 mg protein) were preincubated 
in STC with 1OOpM acetylcoenzyme A at 22°C for 5 min (total 
volume: 200 ~1). The reaction was started by addition of t3H]acetyl- 
coenzyme A (1.6 Ci/mM, final concentration 3 PM) and terminated 
after 0, 1, 2, 4 and 8 min at 22°C by addition of 1 ml icecold STC 
buffer containing 16OrM unlabeled acetylcoenzyme A and subse- 
quent centrifugation. Histones were extracted with 0.4 N HrS04 at 
4°C for 1 h, precipitated with TCA (final concentration 20%) and 
redissolved in 0.1 N NaOH. The radioactivity was counted in a liquid 
scintillation counter. Uptake of label was linear with time up to 
4 min. Specific activities were indicated as pmol/min per mg histone. 
Histone protein concentration was determined according to the pro- 
cedure by Lowry et al. [ll]. 
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2.4. Gel electrophoresis of histones 
Isolated nuclei were lysed in sodium dodecyl sulfate sample buffer 
I121 and aliquots were subjected to electrophoretic analysis. An ali- 
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quot of nuclei was used for determination of the protein content. 
Samples were analyzed by SDS-15% polyacrylamide slab gel elec- 
trophoresis (16 cm long) as described 1121. Equal amounts of protein 
were loaded on each lane. Gels were stained with Coomassie blue. 
Fluorography was performed according to a published procedure [13] 
using preflashed Kodak X-Omat RP film. 
2.5. Thymidine incorporation 
For in vivo labeling DNA with [3H]thymidine, rats were i.p. in- 
jected with 1 &i/g [3H]thymidine (25 Ci/mmol) for 30 min. For in 
vitro labeling 1 ml of AS30D ascites was incubated with 
[‘Hlthymidine at a final concentration of 20pWml at 37°C for 
30 min. Nuclei were isolated as described above. Extraction of DNA 
and counting of radioactivity was done as described elsewhere [14]. 
DNA analysis was performed according to a published procedure 
1151. 
3. RESULTS AND DISCUSSION 
Table I shows histone acetyltransferase (HACT) ac- 
tivities of AS30D hepatomas of different age and of 
normal liver. The maximum of HACT activity occur- 
red 6 days after i.p. inoculation and corresponds to an 
activity of 212% compared to the activity of untreated 
liver. After 12 days the activity decreased to values of 
about 144%. The results indicate a transient increase of 
HACT activity in AS30D hepatomas after i.p. inocula- 
tion of tumor cells. Whether this increased activity of 
histone acetyltransferase in hepatomas is due to 
elevated enzyme levels or whether it reflects alterations 
in the kinetic properties of the enzymes cannot yet be 
decided. 
We used these results as a model to investigate the ef- 
fects of alkylating agents on the HACT activity of 
AS30D hepatomas with different HACT activities. 
These tumors were compared with bening proliferating 
and non-proliferating tissues. It is well known that 
alkylating antitumor agents depress the acetylation of 
histones in tumor cells [8,16]. Our experiments howed 
that the extent of depression correlates with the height 
Table I 
Histone acetyhransferase activity at various days after i.p. 
inoculation of AS30D tumor cells into rats 
n Activity - n Activity + n Depression 
N-mustard N-mustard in % 
AS30D 
5 days 3 197 * 9.1 3 87 f 7.0 3 56 + 5.0 
6 days 6 212 + 8.6” 5 89k44.1 5 62 + 1.6” 
8 days 3 167 + 10.0 3 82 k 7.0 3 50 + 5.1 
12 days 6 144 rt 5.7a 5 73 f 2.7 5 46 + 2.0” 
Liver 100 5 102 + 3.6 - 
a The activity and the depression differed significantly between 6- 
and 12-day-old tumors (P < 0.01, t-test) 
The activity was measured in hepatoma AS30D and normal rat liver 
with and without treatment of N-mustard. All activity values are 
given in % of untreated liver (100%). Each value is expressed as the 
mean + SE of 3-6 experiments (n = number of experiments). 100% 
represents an activity of about 0.2 pmol/min/mg histone 
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of the HACT activity. We found the greatest depres- 
sion (62%) in 6-day-old tumors, 12-day-old tumors 
showed a depression of only about 46% (Table I). In 
normal liver we could not find an inhibition of HACT 
activity. These effects are not due to an increase in dead 
cells produced by the cytotoxic drugs, since the viability 
of cells treated with alkylating agents was 96.9 + 2.3% 
when measured with the Trypan blue method. 
Fig. 1A shows a representative histone acetyltrans- 
ferase activity assay. Nuclei from AS30D hepatoma (6 
days after i.p. inoculation) and liver in the presence and 
absence of N-mustard were compared. After treatment 
with alkylating agents the HACT activities of the 
tumors were lower than the activities of normal livers. 
These data were obtained by counting the labeled nuclei 
in a scintillation counter. Analyzing the same samples 
by SDS gel electrophoresis and fluorography produced 
the same results. Moreover, for all core histones the 
rate of [3H]acetate incorporation was affected to about 
the same extent (Fig. 1B). 
MlnuteS 
1 2 3 4 
Fig. 1. (A) Effect of N-mustard on the histone acetyhransferase 
activity in hepatoma AS30D and host liver 6 days after i.p. 
inoculation. Histones were extracted and the incorporated label was 
measured as described in section 2. The values are normalized in 
terms of mg histone. (B) Fluorogram of acetylated histones. 
[3H]Acetylcoenzyme A labeled nuclei from normal untreated liver 
(lane I), 6-day-old hepatoma after treatment with N-mustard (lane 
2), 12-day-old hepatoma (lane 3), 6-day-old hepatoma (lane 4). 
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Fig. 2. Thymidine incorporation of N-mustard treated and untreated 
6- and 12-day-old AS30D hepatomas in vitro (A) and compared with 
normal liver in vivo (B). Data are presented as the mean of two 
experiments. 
In order to determine the antiproliferative effect of 
N-mustard at various days after i.p. inoculation of 
tumor cells we measured the thymidine incorporation 
in vivo and in vitro (Fig. 2). N-mustard has been shown 
to cause a direct block of DNA replication at the con- 
centrations we used [17]. The in vivo thymidine incor- 
poration correlates well with the data obtained after 
measuring the HACT activity. The 6-day-old tumor 
showed an increased thymidine incorporation and a 
stronger depression after treatment with N-mustard 
compared to 12-day-old tumor (Fig. 2B). The same 
ID 6days liepatect LIveI- 
Fig. 3. The comparison of HCAT activity in benign (hepatectomized 
liver) and malignant (I-day-old AS30D hepatoma) proliferating 
tissue and the effect of Mafosfamid. The HACT activity was 
measured as described previously. Data are presented as the mean of 
two experiments. 
data were obtained when thymidine incorporation was 
measured in vitro (Fig. 2A). 
The comparison of histone acetyltransferase activity 
in benign (hepatectomized liver) and malignant 
(AS30D-Hepatoma) proliferating tissue with non- 
proliferating tissue (normal liver) and the effect of 
cyclophosphamide (Mafosfamid) is shown in Fig. 3. 
Both proliferating tissues showed higher activities than 
liver and a depression of this activity after treatment 
with cyclophosphamide. The 6-day-old tumor showed 
a 300-fold decrease in thymidine incorporation and an 
inhibition of histone acetylation of about 62% after 
treatment with N-mustard. In normal liver the HACT 
activity was not influenced and only a 3-fold decrease 
in thymidine incorporation was seen (Fig. 2B and Table 
I). The thymidine incorporation in normal liver is pro- 
bably not related to DNA replication - the small rate 
of thymidine incorporation may be due to DNA repair. 
The effect of N-mustard may be a combination of 
thymidine transport inhibition [18] and interaction with 
DNA repair. 
These results suggest that the rate of inhibition of 
histone acetylation correlates with the rate of depres- 
sion of thymidine incorporation in proliferating tissues. 
Therefore, the depression of histone acetylation may be 
an important factor for the antiproliferative activity of 
alkylating agents. This could be explained by a variety 
of possible mechanisms [19]. For example, pro- 
liferating tissue might take up more of the drug than 
non-proliferating tissue [20-231, or alternatively, a se- 
cond more sensitive histone acetyltransferase might be 
present in proliferating cells [24]. A replication-linked 
destabilization of chromatin structure can make the 
core histones more vulnerable to alkylating agents, 
and, therefore, the acetylation of core histones will be 
depressed more strongly. This inhibition of acetylation 
would block the necessary displacement of core 
histones during DNA replication [1,25]. In any case, 
the data available so far demonstrate that replication- 
linked histone acetylation in proliferating malignant or 
benign tissues is particularly sensitive to alkylating 
agents. 
Acknowledgements: We are indebted to Professor Dr H. Grunicke 
for helpful discussion and to Dr M. Rittinger for technical assistance. 
REFERENCES 
111 
PI 
t31 
141 
VI 
WI 
Loidl, P. (1988) FEBS Lett. 227, 91-95. 
Doenecke, D. and Gallwitz, D. (1982) Mol. Cell. Biochem. 44, 
113-128. 
Chambers, S.C.A. and Shaw, B.R. (1984) J. Biol. Chem. 259, 
13458-13463. 
Sealy, L. and Chalkley, R. (1979) Arch. Biochem. Biophys. 
179, 78-82. 
Horiuchi, K., Fujimoto, D., Fukushima, M. and Kanai, K. 
(1981) Cancer Res. 41, 1488-1491. 
Weiss, G. and Puschendorf, B. (1988) FEBS Lett. 238, 
205-210. 
143 
Volume 264, number 1 FEBS LETTERS May 1990 
[7] Grunicke, H.H., Yamada, Y., Natsumeda, Y., Helliger, W., 
Puschendorf, B. and Weber, G. (1989) J. Cancer Res. Clin. 
Oncol. 115, 43.5-438. 
[8] Zwierzina, H., Loidl, A., Fuith, L.C., Helliger, W., 
Puschendorf, B. and Grunicke, H. (1984) Cancer Res. 44, 
3336-3339. 
[9] Helliger, W., Hoffmann, J., Maly, K., Doppler, W., Hermann, 
B.J., Hock, W., Puschendorf, B. and Grunicke, H. (1988) Eur. 
J. Cancer Clin. Oncol. 24, 1861-1868. 
[lo] Higgins, G.M. and Anderson, R.M. (1931) Arch. Pathol. 12, 
186-202. 
[l l] Lowry, O.H., Rosebrough, N. J., Farr, A.L. and Randall, R.J. 
(1951) J. Biol. Chem. 193, 265-275. 
(121 Laemmli, U.K. (1970) Nature 227, 680-685. 
[13] Laskey, R.A. and Mills, A.D. (197.5) Eur. J. Biochem. 56, 
335-341. 
1141 Loidl, P., Grobner, P., Csordas, A. and Puschendorf, B. 
(1982) J. Cell. Sci. 58, 303-311. 
1151 Burton, K. (1956) Biochem. J. 62, 315-323. 
[16] Grunicke, H., Csordas, A., Helliger, W., Hauptlorenz, S., 
Loidl, A., Multhaup, I., Zwierzina, H. and Puschendorf, B. 
(1984) Adv. Enzyme Regul. 22, 433-446. 
1171 DeCosse, J.J. and Gelfant, S. (1970) Exp. Cell Res. 60, 
185-190. 
[IS] Grunicke, H., Hirsch, F.. Wolf, H., Bauer, U. and Kiefer, G. 
(1975) Exp. Cell Res. 90, 357-364. 
1191 Connors, T.A. (1984) in: Antitumor Drug Resistance (Fox, 
B.W. and Fox, M. eds) pp. 401-424, Springer, Berlin. 
[20] Goldenberg, G.J., Vanstone, C.L., Israels, L.G. and Bihler, 
I.D. (1970) Cancer Res. 30, 2285-2291. 
[21] Goldenberg, G.J. (1975) Cancer Res. 35, 1687-1692. 
1221 Klatt, O., Stehlin, J.S., McBride, C. and Griffin, A.C. (1969) 
Cancer Res. 29, 286-290. 
[23] Wolpert, M.K. and Ruddon, R.W. (1969) Cancer Res. 29, 
873-879. 
[24] Delpeche, M., Moisand, F. and Kruh, J. (1982) B&hem. Bio- 
phys. Res. Commun. 105, 1561-1586. 
1251 Loidl, P. and Grobner, P. (1987) Nucleic Acids Res. 15, 
8351-8360. 
